AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01004042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.
Study NCT01955655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Since the therapeutic window of Baclofen is narrow, the lowest dose compatible with an optimal response was used.
Study NCT01955655 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03181321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The First Twenty
Description: The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
Study NCT03146182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRP-algorithm
Description: a strategy based on CRP guided antibiotic stewardship
Study NCT03146182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCT-algorithm
Description: a strategy based on PCT guided antibiotic stewardship
Study NCT03196674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback via motion capture
Description: The motion capture system will provide visual and auditory feedback of success, via a large screen, located on the wall. This could be manipulated so that the feedback is provided for a slightly higher range than instructed by the therapist.
Study NCT03200691 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-DCRT or IMRT radiation
Description: Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40 Gy/20f.
Study NCT03200691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody SHR-1210
Description: SHR-1210 (200mg fixed dose every 2 weeks for 2 cycles) will be administered as an intravenous infusion over 60 minutes.
Study NCT03891017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vacuum casting
Description: Participants will be cast using vacuum casting (Ottobock Harmony) method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
Study NCT03891017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hydrostatic casting
Description: Participants will be cast using aqua casting method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
Study NCT03376542 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Testing
Description: Cardiopulmonary exercise testing on treadmill prior to coronary artery bypass grafting surgery
Study NCT01844999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Patient Profile - Prostate (P3P)
Description: Website supporting informed patient decision making about prostate cancer care through tailored education and coaching
Study NCT01844999 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard prostate cancer information websites
Description: Standard prostate cancer information websites (e.g., NCI, ASCO) presented to patients in addition to patient education that is usual in their clinics
Study NCT01806038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RPh Counseling + Outpatient Med Dispensing at Discharge
Description: On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist
Study NCT01806038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discharge Med Dispensing Plus Counseling - Current Practice
Description: At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
Study NCT03001752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap immediate implant
Description: Post-extraction implants will be inserted through open flap, without bone grafting
Study NCT03001752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap immediate implant and bone grafting
Description: Post-extraction implants will be inserted through open flap, adding bone grafting
Study NCT03001752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flapless immediate implant
Description: Post-extraction implants will be inserted without elevating flap or inserting bone grafting
Study NCT01029015 — intervention group
Intervention type: PROCEDURE
Intervention: polysomnography
Description: recording device measuring sleep activity through electrodes attached to the subject
Study NCT04385680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate vaginal solution 0.05%
Description: preoperative vaginal preparation
Study NCT00847834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan 150mg / Hydrochlorothiazide 12.5mg
Description: Once a day
Study NCT00847834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan 150mg
Description: Once a day
Study NCT00975039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST11
Description: WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.
Study NCT00724932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: After the last dose of rocuronium has been administered, participants will receive, according to the randomization, 50 μg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
Study NCT06715176 — intervention group
Intervention type: OTHER
Intervention: Clinical periodontal measurements at baseline (T0)
Description: Full-mouth clinical periodontal measurements, including PD, CAL, GI, and PI were recorded at 6 sites per tooth, except the third molars, at baseline (T0). A manual periodontal probe was used for PD (millimeters) and CAL (millimeters) measurements; the cemento-enamel junction was used as a reference point for the measurement of CAL.
Study NCT01714869 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Swedish Massage
Description: Swedish Massage, once per week for 8 weeks, 60 minutes per session.
Study NCT01541267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aliskiren, eplerenon, telmisartan
Description: aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)
Study NCT03991884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT03991884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT03991884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT03991884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO or IV
Study NCT00724932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: After the last dose of rocuronium has been administered, participants will receive, according to randomization, 10 μg.kg-1 atropine (with neostigmine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
Study NCT03369093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Twice daily doses of injectable amoxicillin
Study NCT00338572 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: Participants in the exercise group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day.
Study NCT03991884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02776514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcort
Description: Fluoroscopic guided injection in the knee joint
Study NCT02776514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich-plasma
Study NCT06715176 — intervention group
Intervention type: OTHER
Intervention: Saliva collection at baseline (T0)
Description: Unstimulated whole saliva was collected from all participants at baseline (T0). The participants were instructed to refrain from mechanical or chemical oral hygiene practices, eating, drinking, and chewing gum for 2 hours prior to sample collection. Every participant rinsed the mouth with tap water for 2 minutes. Ten minutes after rinsing, they were told to allow the accumulation of the saliva in their mouths and then to drain passively the saliva pool from the lower lip into a steril container for 5 minutes.
Study NCT03991884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV
Study NCT04350229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug omission
Description: Drug omission. In the experimental group, dexamethasone will be omitted from the second application of paclitaxel.
Study NCT04350229 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: No drug omission. In the control group, dexamethasone will not be omitted in the second application of paclitaxel.
Study NCT00760604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Comparison of en-bloc vs. non-en bloc esophagectomy
Study NCT00405821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Description: 400mg twice daily for 24 months
Study NCT00405821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily for 24 months
Study NCT02907320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYCLO 3 ® FORT
Study NCT02907320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MPFF
Study NCT02907320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo CYCLO 3 ® FORT
Study NCT02907320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo CYCLO 3 ® FORT
Study NCT02907320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo MPFF
Study NCT02907320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo MPFF
Study NCT06715176 — intervention group
Intervention type: OTHER
Intervention: Scaling and root planing
Description: Periodontitis patients (grade B and C) underwent a program of non-surgical periodontal therapy consisting of conventional quadrant-based scaling and root planing using ultrasonic instruments and manual periodontal curette over four visits at 1-week intervals. All present teeth were instrumented until the root surface was visually and tactilely clean and smooth. Patients who did not respond to treatment at baseline (T0) received a further round of scaling and root planing at three (T3) months post-therapy in order to eliminate residual pockets.
Study NCT06715176 — intervention group
Intervention type: OTHER
Intervention: Clinical periodontal measurements at T1, T3, and T6.
Description: Full-mouth clinical periodontal measurements were performed for all periodontitis patients (grade B and C) at one (T1), three (T3) and six (T6) months after scaling and root planing.
Study NCT06715176 — intervention group
Intervention type: OTHER
Intervention: Saliva collection at T1, T3, and T6.
Description: Unstimulated whole saliva were collected from all periodontitis patients (grade B and C) at one (T1), three (T3) and six (T6) months after scaling and root planing.
Study NCT03585192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Group
Description: 1. If the newborn is vigorous (crying, good respiratory effort, good tone) after vaginal delivery, newborn will be able to go directly to Mother's chest for immediate SSC~2. A pulse oximeter will be placed on the newborn's right wrist. Saturations will be monitored on a pulse oximeter located next to the Mother's bed for the first hour of life.
Study NCT03585192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warmer Group
Description: 1. Newborn will go to the radiant warmer, pulse oximeter placed on newborn's right wrist, and saturations will be monitored on the Panda Warmer.~2. If stable per Baby RN after 20 minutes of observation, the newborn will be placed on Mother's chest for SSC. Vital signs will be monitored for the first hour of life.
Study NCT00338572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Exercise and Diet Program
Description: Participants in this group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day. They will meet with a dietician and will be encouraged to reduce their caloric intake by incorporating low-fat, high-fiber foods into their diet.
Study NCT00640549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.
Study NCT00640549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.
Study NCT00580918 — intervention group
Intervention type: OTHER
Intervention: functional magnetic resonance imaging fMRI
Description: functional magnetic resonance imaging fMRI
Study NCT02051491 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BP-NCPAP
Description: Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm H2O and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on FiO2 requirements.
Study NCT02051491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIHFV
Description: The initial settings will be a MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
Study NCT04103723 — intervention group
Intervention type: PROCEDURE
Intervention: Preoperative premedication
Description: Every patient with or without a preoperative premedication with midazolam before surgery.
Study NCT00490100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Increlex
Study NCT02776514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suplasyn1
Study NCT02776514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04788160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical SNAGs along with conventional therapy
Description: cervical SNAG half rotation technique will be performed with the patient sitting on a chair in the erect posture. The therapist placed his thumb over thumb over the transverse process of C1. Then, he glided ventrally with active rotation of the restricted site 10 times holding for 10 seconds with overpressure at end of the rotation with 30 second rest in between each repetition and 3 session/week for 4 weeks.~* Conventional therapy will include:~* Hot pack over the cervical region for 10 minutes.~* TENS for 10 minutes.~* Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions with 3 sessions/week for 4 weeks.~* Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~* Cervical flexor strengthening will be done 10 times in sitting position.
Study NCT04788160 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Therapy
Description: * Patients in this group will undergo only conventional therapy which will include:~* Hot pack for 15 minutes.~* TENS for 10 minutes.~* Furthermore, general stretching the upper cervical muscles will be done with 5 repetitions each 3 sessions/week for 4 weeks.~* Isometric cervical extensor exercise with 10 seconds hold for 10 times will be done.~* Cervical flexor strengthening will be given to the patient by the therapist, 10 times in sitting position.
Study NCT01568866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib is administered over 30 minutes as an infusion.
Study NCT01568866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)
Study NCT01568866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.
Study NCT01568866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.
Study NCT03698266 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Needle knife fistulotomy
Description: A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP
Study NCT01516866 — intervention group
Intervention type: PROCEDURE
Intervention: Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
Description: Subjects who will be enrolled will be those who will be starting treatment (as part of standard of care or as part of another trial) with either a microtubule directed chemotherapy regimen (cohort A), or AR-directed therapy (cohort B). All subjects will have a baseline NaF PET/CT scan (baseline #1), performed within days prior to starting either chemotherapy or AR-directed therapy. A subset of subjects (up to 20 subjects per site, 60 total) will undergo a second NaF PET/CT scan (baseline #2) within 1-8 days of the initial scan to determine repeatability of NaF PET/CT scanning. Subjects in cohort A will undergo another NaF PET/CT scan at week 8 (+/- 1 week). Subjects in cohort B will undergo two additional NaF PET/CT scans at weeks 6 and 12 (+/- 1 week).
Study NCT03493776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VZV subunit vaccine
Description: VZV subunit vaccine
Study NCT03493776 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VZV subunit vaccine
Description: VZV subunit vaccine